Aequus Pharmaceuticals Inc Stock (OTCMKTS:AQSZF)


$ 0.10
Today's Range
$ 0.10 - $ 0.10
52-Week Range
$ 0.07 - $ 0.23
Market Cap
$ 12.81M

About Aequus Pharmaceuticals Inc (OTCMKTS:AQSZF)

(OTCMKTS:AQSZF) Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.
Show more

AQSZF Stock Price

Statistics Highlights (OTCMKTS:AQSZF)

Shares Outstanding 132.63M Beta 0.50
Public Float 119.83M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders 14.51% Ex-Dividend Date
Held by Institutions 5.69% IPO Date -

AQSZF Financial Summary

Dec 20 Dec 19 Dec 18
Revenue $2.59M $1.63M $1.41M
EBITDA $-314.80K $-2.38M $-2.62M
Net Income $-1.05M $-3.11M $-2.80M
Total Assets $3.13M $1.67M $2.00M
Total Cash $1.72M $484.51K $369.89K
Total Debt $ $ $
Jun 21 Mar 21 Dec 20
Revenue $651.52K $491.82K $851.19K
EBITDA $-345.85K $-463.83K $-130.60K
Net Income $-479.04K $-621.66K $-165.38K
Total Assets $4.84M $4.48M $3.13M
Total Cash $3.63M $3.34M $1.72M
Total Debt $ $ $


What is today's stock price of Aequus Pharmaceuticals Inc (OTCMKTS:AQSZF)?

  • The current stock price of Aequus Pharmaceuticals Inc (OTCMKTS:AQSZF) is $0.10.
  • Today AQSZF stock price opened at $0.10 after previous close of $0.10.
  • During the day, Aequus Pharmaceuticals Inc stock quote has varied from a low of $0.10 to a high of $0.10.

What is Aequus Pharmaceuticals Inc's 52-week change?

  • AQSZF 52-week high stock quote is $0.23, which is 137.40% above the current share price.
  • The Aequus Pharmaceuticals Inc (OTCMKTS:AQSZF) 52-week low stock price is $0.07, which is 31.90% below the current share price.
  • Aequus Pharmaceuticals Inc share price volatility (52-week beta) is 0.50.

Aequus Pharmaceuticals Inc (OTCMKTS:AQSZF) FAQ

How Much is Aequus pharmaceuticals inc Worth?

Aequus pharmaceuticals inc's worth today based on market capitalisation is $12.81M

How much dividend does Aequus pharmaceuticals inc Pay?

The current annualized dividend payout for AQSZF stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Aequus pharmaceuticals inc's "Dividend" Section

What is Aequus pharmaceuticals inc’s Price to Earning (PE) ratio?

AQSZF stock also has a Price to Sales (P/S) ratio of 4.90.

What is the Aequus pharmaceuticals inc's ticker?

Aequus pharmaceuticals inc trades on the OTC Markets stock market in USA under the ticker symbol "AQSZF". Aequus pharmaceuticals inc’s stock symbol can also be displayed as "OTCMKTS:AQSZF".

Who are the owners of Aequus pharmaceuticals inc?

Aequus pharmaceuticals inc (OTCMKTS:AQSZF) is owned by 5.69% institutional shareholders and by 14.51% insiders. The rest is owned by the public.
Explore More Details on Aequus pharmaceuticals inc's “Ownership” Section

Who are the key executives of Aequus pharmaceuticals inc (AQSZF)?

Aequus pharmaceuticals inc's key executive team includes the following managers:

  • Mr. Douglas Glen Janzen, Chairman & CEO (1969)
  • Ms. Ann Fehr CGA, CPA, CFO & Corp. Sec. (1969)
  • Mr. Stuart Fowler, Strategic Commercial Advisor & Independent Director (NA)
  • Mr. Grant Larsen, Chief Commercial Officer (NA)

What is Aequus pharmaceuticals inc’s Sector & Industry Classification?

Aequus pharmaceuticals inc (OTCMKTS:AQSZF) is classified under the "Healthcare" sector and under the "Drug Manufacturers-Specialty & Generic" industry.

How many employees work for Aequus pharmaceuticals inc?

Currently the number of employees working for Aequus pharmaceuticals inc is 0.

Where are Aequus pharmaceuticals inc's Headquarters?

Aequus pharmaceuticals inc (OTCMKTS:AQSZF) is headquartered in BC, Canada.

What are Aequus pharmaceuticals inc's Address and Phone Number?

Aequus pharmaceuticals inc’s mailing address is 200 Granville Street, Vancouver, BC, Canada, V6C 1S4.
The company’s phone number is 604 336 7906.

What is the official website for Aequus pharmaceuticals inc?

Aequus pharmaceuticals inc’s official website is